创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

FAN Lu, CUI Bingbing, LU Tao, CHEN Yadong. Research Progress of Small Molecule Spleen Tyrosine Kinase Inhibitors[J]. Progress in Pharmaceutical Sciences, 2021, 45(1): 44-54.
Citation: FAN Lu, CUI Bingbing, LU Tao, CHEN Yadong. Research Progress of Small Molecule Spleen Tyrosine Kinase Inhibitors[J]. Progress in Pharmaceutical Sciences, 2021, 45(1): 44-54.

Research Progress of Small Molecule Spleen Tyrosine Kinase Inhibitors

  • Spleen tyrosine kinase (Syk) is a cytoplasmic non-receptor protein tyrosine kinase that is mainly expressed in hematopoietic cells. It not only plays a vital role in immune receptor signaling, but also regulates other different biological functions, including cell adhesion, proliferation, osteoclast maturation, and platelet activation. In recent years, Syk has become an attractive drug target in hematological malignancies, autoimmune, inflammation and other diseases. This article introduces the structure and activation mechanism of Syk as well as the relationship between its signaling pathways and diseases, and reviews the clinical research progress of oral small molecule Syk inhibitors, aiming to provide reference for further research and application.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return